Kornimate/medical-research-clean huggingface dataset:
thoracic tumours register

Conditions: Thoracic Tumors

Summary: observational, multicenter study in patients with lung cancer and other thoracic tumors. the gecp, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. this could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. the aim of the register is to explore all data available of all patients treated because of thoracic tumours.

observational, multicenter study in patients with lung cancer and other thoracic tumors. in a prospective and retrospective way, information will be obtained from the clinical history of each patient. in europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. however, the priorities should be to prevent lung cancer by implementing anti-smoking policies and controlling asbestos exposure throughout europe, such as was recommended by the world health organization (who) in 2008.14 other priorities are to reduce levels of residential radon in risk areas, and early diagnosis to improve the results of surgery, which is still the main curative treatment. the variability in the diagnostic process, treatment and advocacy, as well as the anticipated increase in associated mortality in spain in coming years, has stimulated the creation of an epidemiological, observational, multicenter study of cases of lung cancer and other thoracic tumors diagnosed and treated by medical personnel, including both thoracic surgeons and medical oncologists. data from this study will be collected retrospectively and prospectively, so as to enable an extensive study of the epidemiological and therapeutic factors related to the disease.

Eligibility criteria:
inclusion criteria: * patients with thoracic disease, treated with an active treatment or not treated (only palliative care) exclusion criteria: * patients with other type of tumours
a dose escalation study of a combination antihypertensive drug in the treatment of various groups of patients who do not respond to single drug treatment of their high blood pressure

Conditions: Hypertension

Summary: the initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). the final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. all three medications being tested have been approved by the fda for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.


Eligibility criteria:
inclusion criteria: * \>= to 18 years of age * hypertension uncontrolled on current monotherapy * females: * negative serum pregnancy test at screening * post menopausal or have had a hysterectomy or tubal ligation or practicing approved methods of birth control exclusion criteria: * pregnant females * uncontrolled hypertension with multiple drugs, except for hydrochlorothiazide/triamterene * diabetes requiring insulin * serious disorders that may limit the ability to evaluate the efficacy or safety of treatment * history of myocardial infarction, bypass graft, angioplasty or heart failure within the past 6 months * history of class iii or iv congestive heart failure * history of stroke or transient ischemic attack within the last 1 year
post marketing surveillance study on linezolid

Conditions: Gram-Positive Bacterial Infections

Summary: the purpose of this study is to determine if linezolid is safe for adult filipino patients diagnosed with gram positive infections.

the subjects were identified after the physician decided to prescribed the drug to the subject.

Eligibility criteria:
inclusion criteria: * has clinical diagnosis of of the following, including cases with concurrent bacteremia, when suspected or known to be caused by susceptible strains of anaerobic or aerobic gram positive microorganisms - nosocomial pneumonia, community acquired pneumonia, complicated skin and skin structure infections, uncomplicated skin and skin structure infection, and vancomycin-resistant e. faecium * male or female, 18 years old and above exclusion criteria: * known hypersensitivity * subjects diagnosed with pure gram-negative infection

Keywords: non-interventional non-comparative open-label study safety linezolid gram positive infections filipino
effect of kinesiotaping application in preterm infants undergoing noninvasive ventilation

Conditions: Preterm Infant

Summary: kinesiotaping (kt) applied to the thorax is believed to enhance breathing by supporting the respiratory muscles. infants born premature usually have respiratory problems because of depletion of surfactant and respiratory muscle weakness. therefore, we are going to use kt for premature infants in nicu who are undergoing non-invasive ventilation. forty-two participants divided into two groups. the first group will be applied kt to chest wall, abdomen and diaphragm, and the other group will not receive any kt application during non-invasive ventilation. kt application will be going on as long as the infant underwent non-invasive ventilation. we are going to measure blood gas parameters (ph, pco2, po2, base excess), respiration rate, peak heart rate, percentage of fio2, fio2/po2 rate, peep and pip values before non-invasive ventilation, 2 hours after non-invasive ventilation, within 72 hours and shortly before weaning from non-invasive ventilation.


Eligibility criteria:
inclusion criteria: * inpatient infants in nicu, born in baskent university ankara hospital, undergoing non-invasive ventilation and age between 24-36.6 weeks. exclusion criteria: * infants with multiple kongenital anomaly, hypoxic ischemic encephalopathy, tracheoesophageal fistula, diaphragmatic hernia.

Keywords: preterm infants kinesiotape ventilation respiratory muscles
a phase i/ii clinical study of lbl-024 in patients with advanced malignant tumors

Conditions: Advanced Solid Tumor

Summary: to evaluate the phase i/ii clinical study of lbl-024 in the treatment of patients with advanced malignant tumors

this trial is a single-arm, open-label, phase i/ii clinical study of lbl-024 in patients with advanced malignant tumors. the phase i dose escalation and pk expansion phase plans to include patients with advanced malignant tumors who have failed previous standard treatment or do not have standard treatment or are not applicable to standard treatment at this stage. the phase iia indication expansion phase plans to include patients with advanced malignant tumors , and evaluate the safety, tolerability, pharmacokinetic (pk) characteristics, immunogenicity and preliminary efficacy. single-arm registry clinical study to be conducted in phase iib. this trial includes two parts: part i: a phase i/iia clinical study on the safety, tolerability, pk and efficacy of lbl-024 in patients with advanced malignant tumor. part ii:phase iib is a pivotal single-arm clinical study.

Eligibility criteria:
inclusion criteria: 1. agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form; 2. 18-75 years old (including boundary value), no gender limit in the i/iia trial phase；18-80 years old (including boundary value), no gender limit in the iib trial phase； 3. subject has adequate organ and bone marrow function，conforming to laboratory test results: 4. the expected survival time is at least 12 weeks 5. ecog score is 0-1 6. males with fertility and females of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception sets，etc）; women of childbearing age include pre-menopausal women and women within 2 years after menopause. women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. exclusion criteria: 1. receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment; 3. medical history of immunodeficiency including positive hiv antibody test; 4. women who are pregnant or breastfeeding; 5. the investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study
dual diagnosis training trial

Conditions: Training Group

Summary: this is a clinical trial, with participants undergoing the 16 hour spectrom training, and completing 2 assessments before and after training (the psychotropic knowledge questionnaire-revised and the management of aggression and violence attitude scale-revised-id).


Eligibility criteria:
inclusion criteria: * inclusion criteria are individuals who work in the 3 arca group homes or in the unm psychiatric center and who are fluent in english and 18 years and older exclusion criteria: * all participants must be fluent in english because for this pilot study we do not have funds to translate study materials.

Keywords: intellectual disability
clinical characteristics of pruritus and evaluation of quality of life in patients with bullous pemphigoid

Conditions: Bullous Pemphigoid

Summary: whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact on quality of life have been little studied. the objective of this study is to learn more about pruritus characteristics of patients with bullous pemphigoid, and in consequence to better understand the pathophysiology of pruritus, and then to better treat pruritus in this condition.


Eligibility criteria:
inclusion criteria: * adult * pruriginous bullous pemphigoid lately diagnosed. * without pb treatment * mms (mini mental state examination) ≥ 21 * in hospitalization or consultation exclusion criteria: * pregnant woman * nursing women

Keywords: pruritus bullous pemphigoid
study of voy-101 in patients with advanced non-neovascular age-related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: the phase 1 safety study of voy-101 comprises of escalating dose cohorts, followed by a phase 2a.

this is a prospective, open-label, multi-center phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (ivt) injection of escalating dose levels of voy-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (amd).

Eligibility criteria:
inclusion criteria: * are ≥50 years of age at the time of consent. * are willing and able to understand and provide written informed consent. * are willing and able to return for scheduled treatment and follow-up examinations. * are able to undergo etdrs bcdva testing and ophthalmic imaging. * well-demarcated ga secondary to amd in the absence of mnv and in the absence of history of mnv. * absence of signs of non-exudative mnv. * additional ocular inclusion criteria for study eye. * meet certain genotype criteria for risk of amd. exclusion criteria: * are women of childbearing potential (wocbp) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study. * additional systemic, ocular, and genetic exclusion criteria.
an open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia

Conditions: Schizophrenia

Summary: accumulating evidence suggests a role of oxidative stress in the pathophysiology of schizophrenia. the potent antioxidant sulforaphane (sfn) is an organosulfur compound derived from a glucosinolate precursor found in cruciferous vegetables such as broccoli, brussels sprouts and cabbage. the protection afforded by sfn is thought to be mediated via activation of the nf-e2-related factor-2 (nrf2) pathway and subsequent up-regulation of phase ii detoxification enzymes and antioxidant proteins, through an enhancer sequence referred to as the electrophilic responsive element or antioxidant responsive element. recently, we reported that sfn could attenuate behavioral abnormalities in mice after the nmda receptor antagonist phencyclidine. considering the potent antioxidant effects of sfn, we have a hypothesis that sfn would be a potential therapeutic drug for schizophrenia. the purpose of this study is to determine whether sfn-rich broccoli sprout extract have beneficial effects in patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * schizophrenia for dsm-iv tr criteria * patients are treated with an antipsychotic drug (risperidone, olanzapine, quetiapine, perospirone, aripiprazole, blonanserin, paliperidone). * patients are stable for 4-weeks for antipsychotic medication. exclusion criteria: * patients treated with clozapine * patients treated with two or more antipsychotic drugs * pregnant or breast-feeding women * patients treated with sulforaphane for more than 8-weeks in the past.

Keywords: schizophrenia sulforaphane psychosis cognition oxidative stress antioxidant anti-inflammatory
geriatric assessment screening tool for the identification of at-risk older adults who are undergoing cancer treatment

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this phase ii trial investigates how easy it is to incorporate a nursing led geriatric assessment screening tool into a busy oncology practice, in order to identify at-risk older adults being evaluated for cancer treatment. this screening tool may help identify at-risk patients who can be referred for more in depth assessment, allowing for the creation of an individualized treatment plan that puts the patient's safety and personal goals as a priority.

primary objective: i. to determine the feasibility of training nurses to administer the geriatric 8 (g8) screening tool in an oncology practice, to identify older patients (\> 65 years old \[y/o\]) that would benefit from a more extensive comprehensive geriatric assessment (cga). secondary objective: i. to report the positive predictive value of the g8 screening tool with the final frailty designation determined by the comprehensive geriatric assessment completed in patients referred to the senior adult oncology center (saoc). outline: phase i: registered nurses receive training on how to administer the g8 screening tool utilizing an epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician. phase ii: patients complete the g8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their electronic health record (ehr) flowsheet. patients who score =\ 15 on the g8 are made aware of their results without any referral generated.

Eligibility criteria:
inclusion criteria: * nurses: assigned to two designated cancer clinics at sidney kimmel cancer center (skcc) center city, the renal cell carcinoma (rcc) and lymphoma/myeloma clinics * patients: 65 years and older * patients: diagnosis of cancer exclusion criteria: • patients: inability to answer or have caregiver answer questions on screening tool
comparison of early results of mobile and fixed insert unicondylar knee prosthesis.

Conditions: Knee Osteoarthritis

Summary: comparison of the early clinical and radiological results and patient satisfaction of the mobile and fixed insert unicondylar knee prostheses routinely used in the clinic.

unicondylar knee prosthesis operation will be performed on patients with unicompartmental knee arthrosis who apply to our clinic. patients will be randomized to use mobile or fixed inserts. after 1 year of follow-up, sf-36, koos and hss scores will be taken to examine the clinical satisfaction of the patients. in addition, radiological evaluation will be made for the presence of osteolysis at the tibial implant interface between both groups.

Eligibility criteria:
inclusion criteria: * patients with degenerative knee arthritis with only one compartment affected exclusion criteria: * inflammatory arthritis * tricompartmental arthritis * patients with fixed varus deformity greater than -10 degrees * patients with fixed valgus deformity greater than -5 degrees * patients with knee range of motion less than 90 degrees * patients with more than 10 degrees of flexion contracture"

Keywords: unicompartmental knee osteoarthritis unicompartmental knee prosthesis mobile insert fixed i̇nsert
corneal epithelial mapping in diabetics

Conditions: Cornea Epithelial Mapping

Summary: the corneal epithelium is the outermost layer that covers the front of the eye; it not only functions as a barrier that blocks the passage of foreign material, but also plays an important role in maintaining high optical quality. the stem cells in the basal layer of the limbal epithelium hold a physiological significance in the renewal and metabolism of corneal epithelium, particularly under stressful situations.

the cornea in diabetic patients suffers from cellular dysfunction and dysfunctional repairal mechanisms, which include recurrent erosions, delayed wound healing, ulcers, and edema. in addition and undoubtedly related to epithelial dysfunction, alterations in epithelial basement membrane occur.

Eligibility criteria:
inclusion criteria: 1. the patients aged between 40- 60 years old of both genders. 2. the patients in (group a) should be diabetics for more than 10 years and free from any other systemic diseases with diabetic macular edema (by oct). 3. the patients in (group b) should be diabetics for more than 10 years and free from any other systemic diseases without diabetic macular edema (by oct). 4. the patients in (group c) should be free of any systemic diseases and normal macular thickness (by oct) exclusion criteria: 1. previous history of any intraocular surgery, intravitreal injection, laser or refractive surgery. 2. ocular surface disorders (e.g. dry eye) or any corneal pathology. 3. corneal scars or epithelial dystrophies. 4. use of any topical medications. 5. elevated iop, pregnancy or lactation.

Keywords: cornea epithelium oct diabetes
the comacs study: a comparison of methylphenidates in an analog classroom setting

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study was designed to compare concerta extended release tablets with metadate cd capsules in children with adhd who were between 6 and 12 years old. the effects on adhd symptoms, and any side effects of treatment, were measured for 12 hours after dosing in a simulated classroom. the treatments were blinded and the effects were compared with a placebo.


Eligibility criteria:
inclusion criteria: * 6 -12 years of age, inclusive * have a diagnosis of adhd * receiving an approved form of mph (methylphenidate) and have demonstrated clinical improvement during this treatment. exclusion criteria: * iq below 80. * the patient, or a first-degree relative, has a confirmed diagnosis of tourette's syndrome or a clinically significant tic disorder. * history of seizures (excluding uncomplicated childhood febrile seizures). * myocardial infarction within 3 months of study entry, or has a history of cardiac disease, congenital cardiac abnormality, glaucoma, hyperthyroidism. * comorbid psychiatric diagnosis. * exhibits extreme aggressive behavior or destruction of property, marked anxiety, tension, or agitation.

Keywords: adhd methylphenidate metadate cd concerta comacs attention deficit hyperactivity disorder (adhd)
a study of tarceva (erlotinib) to compare two different doses in in currently smoking patients with advanced or metastatic non-small cell lung cancer (currents)

Conditions: Non-Small Cell Lung Cancer

Summary: this prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib \[tarceva\] on progression-free survival, response and disease control rates and overall survival in patients with advanced or metastatic non-small cell lung cancer (nsclc) after failure of first-line platinum-based chemotherapy. patients must be current smokers and not intending to stop smoking during the study. patients will be randomized to receive either 150 mg or 300 mg of study drug as single daily oral doses. treatment will continue until disease progression.


Eligibility criteria:
inclusion criteria: * adult patients aged ≥18 years * inoperable, locally advanced (stage iiib/iv) with supraclavicular lymph node metastases or malignant pleural or pericardial effusion) or metastatic (stage iv) non-small cell lung cancer (nsclc) * disease must be characterized according to response evaluation criteria in solid tumors (recist) criteria * patients have received one prior platinum-based chemotherapy regimen for advanced nsclc, but must have recovered from any treatment-related toxicity * eastern cooperative oncology group (ecog) performance status 0-2 * life expectancy ≥12 weeks * current cigarette smoker (having smoked \>100 cigarettes in entire lifetime and currently smoking on average ≥1 cigarette per day), not intending to stop during the study exclusion criteria: * prior antibody or small molecule therapy against epidermal growth factor receptor (egfr) * radiotherapy within 28 days prior to enrollment * received more than one line of chemotherapy for locally advanced/metastatic nsclc (first-line maintenance chemotherapy after first-line platinum-based chemotherapy is allowed)